We partnered with Dr. Jordana Schachter, a Quebec Dermatologist, who has provided a reflection of her thoughts on the results throughout the final report.
I'm surprised at how low 'mode of action' ranked in importance.
"It’s interesting to see how many respondents believe abrocitinib should be second line to dupilumab. It will be interesting to see if the government will agree in how they organize reimbursement.
There seems to be no census on what to do in cases of difficult to control facial dermatitis. More research is likely needed and guidelines developed.
When a treatment isn’t working we seem to decrease duration between doses. I’d be interested to see if this differed based on province.